Abdominal Tuberculosis: Experience from Two Tertiary-Care Hospitals in the Paris Region

Am J Trop Med Hyg. 2021 Jan;104(1):223-228. doi: 10.4269/ajtmh.20-0023.

Abstract

Abdominal tuberculosis (ATB) is uncommon and not very well known by clinicians. We describe the characteristics, evolution, and treatment of patients with ATB in two large hospitals in the Paris region. We reviewed all records of patients treated for ATB, from January 01, 2010 to December 01, 2016, diagnosed by bacteriological and/or histological methods or highly suspected because of clinical/radiological features. We included 80 patients, with a median (IQR) age of 39 (29-50) years, with 56.2% being males. Among them, 63.7% had African origins, 15% Asian, and 11.2% European. Twenty-nine had a cause of immunosuppression (n = 21 HIV infection). The main abdominal localizations were lymph nodes (72.5%), peritoneum (62.5%), and solid organs (25%). Extra-abdominal localizations were recorded in 65 (81.2%) patients. Tuberculosis was proven bacteriologically in 71%, histologically in 50%, and solely clinical/radiological in 10% of cases. Patients received standard therapy for a median duration of 9 months, with a favorable outcome. Corticosteroid therapy was used in 15 cases, either for paradoxical reaction or to prevent complications. Abdominal TB was mainly represented by lymphatic and peritoneal localizations, proven bacteriologically, and associated with extra-abdominal localizations in most cases. The use of steroids remains controversial, but it does not seem systematically needed in case of abdominal involvement.

MeSH terms

  • Abdomen / pathology*
  • Abdominal Pain / etiology
  • Adult
  • Antitubercular Agents / therapeutic use
  • Diagnosis, Differential
  • Emigrants and Immigrants
  • Female
  • Humans
  • Male
  • Middle Aged
  • Paris / epidemiology
  • Retrospective Studies
  • Tertiary Care Centers*
  • Tuberculosis / drug therapy
  • Tuberculosis / epidemiology*
  • Tuberculosis / pathology*

Substances

  • Antitubercular Agents